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ABSTRACT
Introduction: Changes to Treatment and
Outcomes in Patients with Type 2 Diabetes
Initiating Injectable Therapy (CHOICE) is a
European prospective, observational cohort
study assessing time to, and factors
associated with, a significant change in
therapy after type 2 diabetes patients initiate
their first injectable glucose-lowering therapy,
and these patients’ clinical outcomes over
24 months. The authors report baseline data
and factors associated with the injectable
treatment regimen.
Methods: Demographic, clinical, and
healthcare resource-use data were collected at
initiation of injectable therapy and analyzed
using univariate tests between cohorts and
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Results: Overall, 1,177 patients initiated
exenatide twice daily (b.i.d.) and 1,315
initiated insulin. Most patients were recruited
by secondary-care physicians. Univariate
analyses revealed statistically significant
differences between the characteristics of
patients who initiated exenatide b.i.d. and
patients who initiated insulin. On multivariate
analysis, higher body mass index [BMI; 5 kg/m2
higher: odds ratio (OR) 2.10, 95% confidence
intervals (CI) 1.84–2.40], lower glycated
hemoglobin (HbA1c; 1% higher: OR 0.77, 95%
CI 0.69–0.86), and lower age (5 years older: OR
0.82, 95% CI 0.76–0.88) were the variables most
strongly associated with increased probability of
receiving exenatide b.i.d. (P\0.0001). Patients
initiating exenatide b.i.d. had a mean BMI of
35.3 ± 6.5 kg/m2, HbA1c of 8.4 ± 1.4%, and age of
58 ± 10 years, compared with 29.7 ± 5.4 kg/m2,
9.2 ± 1.9%, and 64 ± 11 years, respectively, in
patients initiating insulin (P\0.0001). Other
characteristics significantly associated with
exenatide b.i.d. initiation were ‘‘disinhibited
eating’’ (Diabetes Health Profile-18), lower
random blood glucose, less blood glucose self-
monitoring, lower low-density lipoprotein
cholesterol, and receipt of diet/exercise advice.
Conclusions: Patients who initiated exenatide
b.i.d. were on average younger and more obese
with lower HbA1c than those initiating insulin.
Keywords: Exenatide; Insulin; Type 2 diabetes
mellitus
INTRODUCTION
During the enrollment period for the CHanges to
Treatment and Outcomes in Patients with Type 2
Diabetes Initiating Injectable Therapy (CHOICE)
study, exenatide twice daily (b.i.d.), the first
approved glucagon-like peptide-1 (GLP-1)
receptor agonist, was available in Europe for
use in combination with metformin and/or a
sulfonylurea in patients with type 2 diabetes
mellitus (T2DM) with insufficient glycemic
control on maximal doses of these medications.
Indications for exenatide b.i.d. in Europe have
subsequently been expanded to include use in
combination with thiazolidinediones (in 2010)
and as adjuvant therapy with basal insulin, with
or without metformin and/or pioglitazone, in
patients who had not achieved adequate
glycemic control with these agents (in 2012). In
head-to-head phase 3 clinical trials, exenatide
b.i.d. and insulin (glargine and biphasic insulin
aspart) provided similar glycemic control in
patients whose diabetes was not controlled
with oral antidiabetic medications (OADs).
Exenatide b.i.d. treatment was associated with
weight loss, while patients randomized to
insulin typically gained weight [1–3]. Metabolic
improvements with exenatide b.i.d. were
maintained in a subset of patients treated for
3.5 years [4].
While randomized, controlled trials are the
reference standard for assessing the efficacy and
safety of therapy, large, observational studies are
necessary to determine how glucose-lowering
medications are used in clinical practice and to
evaluate their effectiveness and safety in this
setting [5, 6]. The patterns of exenatide b.i.d.
usage in clinical practice across Europe have not
previously been evaluated. For example, it is
unclear which patients requiring injectable
glucose-lowering therapy are initiated on
exenatide b.i.d. A comparison of the baseline
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characteristics of patients initiating exenatide
b.i.d. and insulin is, therefore, of interest and
could indicate whether the selection of
injectable therapy is in accordance with known
clinical differentiation and published guidelines
[7]. Other gaps in knowledge include how, when,
and why treatment is intensified or switched
(e.g., by the addition of other glucose-lowering
medications or by the substitution of one insulin
regimen with another) and the clinical response
in routine care. Primary-care databases, the
principal source of retrospective observational
data, are of limited use in this regard because
exenatide b.i.d. is commonly (although not
exclusively) initiated in secondary care.
CHOICE is the first European observational
study conducted specifically to address this lack
of evidence. CHOICE is an ongoing, prospective
cohort study designed to assess the time to a
significant subsequent change in therapy among
patients who initiate their first injectable glucose-
lowering therapy with either exenatide b.i.d. or
insulin (the only injectable treatments available
when this study commenced) in Europe. The
study also aimed to describe the characteristics of
patients with T2DM initiating injectable therapy,
factors associated with treatment changes, and
clinical outcomes and common adverse events
observed over 24 months. CHOICE is being
conducted in six European countries and will be
completed in 2012. This paper reports the
baseline characteristics of enrolled patients and




CHOICE is a prospective, multinational, non-
interventional observational study being
conducted in Belgium (31 sites), Denmark
(eight sites), France (71 sites), Germany (130
sites), Greece (49 sites), and Sweden (33 sites).
The primary endpoint is time spent on initial
injectable regimen (exenatide b.i.d. or insulin)
before significant treatment change. Significant
treatment change is defined as at least one of
the following (and does not include switching
between brands of the same class/type of
insulin): addition of a new medication (any
route of administration) for treatment of T2DM;
a change in the number of times insulin is
administered per day; discontinuation of any
exenatide b.i.d./insulin initiated at baseline;
substitution of a human insulin for an analog
insulin or vice versa.
Secondary objectives include assessment of
characteristics of patients initiating each
treatment, factors associated with injectable
treatment regimen, and clinical and patient-
reported outcomes.
Eligible for inclusion were adults aged
C18 years initiating their first injectable
glucose-lowering therapy with exenatide b.i.d.
or insulin for the treatment of T2DM in routine
clinical practice. At study entry patients could be
taking any OADs. Patients were initiated on
either exenatide b.i.d. or insulin according to
clinical decision making, and were then
informed about CHOICE and invited to
participate. Patients gave written informed
consent for the use of their data. Appropriate
ethical review board approval was obtained for
this study.
Patients have been assessed at study visits at
the time of initiation of injectable therapy
(baseline, reported here) and approximately 3,
6, 12, 18, and 24 months thereafter, as per
routine care. Patients referred from the study
site to another healthcare provider during the
study have been followed up by contacting, and
obtaining the consent of, the new provider and
by postal patient questionnaires. Interim
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analyses are planned at baseline, 6, and
12 months, with the final analysis after the
24-month visit.
Data Collected
At baseline (initiation of injectable therapy),
standard clinical data were collected from each
patient, i.e.,: demographic characteristics;
clinical characteristics (current and historical),
including glycated hemoglobin (HbA1c; at
initiation and over previous 2 years), weight,
blood pressure, lipid levels, and diabetes
complications; retrospectively recalled incidence
of self-reported hypoglycemic episodes (over the
preceding 3 months) and gastrointestinal
symptoms (over the preceding 4 weeks);
previous and ongoing diabetes therapy and care;
concomitant medications; and patient-reported
outcome measures of health status and
functioning, including the Diabetes Health
Profile (DHP)-18 instrument [8]. Data were
collected using an electronic data capture form:
clinical data were entered by the investigator
(or proxy); patient-reported outcome data were
provided by the patient and transferred to the
same form by the site personnel.
Analysis
Sample Size Justification
The study aimed to recruit a maximum of 800
patients per country/country group with a ratio
of approximately 60% initiating insulin and
40% initiating exenatide b.i.d. The sample size
calculation was performed by Monte-Carlo
simulation assuming patient drop-out rates of
10–15% per year and median time to significant
treatment change of 9.0 months for the
exenatide b.i.d. cohort and 8.6 months for the
insulin cohort [9, 10]. The insulin cohort was
larger than the exenatide b.i.d. cohort owing to
greater variability in the former (linked to use of
different insulin regimens), which necessitated
a larger population in order to achieve similar
precision for the estimation of time to
treatment change [95% confidence intervals
(CI) of 3–4 months width around median
within countries and cohorts].
The following strategy was used to achieve
the required number of patients in each cohort
without intervening in treatment decisions
made during normal clinical practice: once a
cohort within a participating country was filled,
investigating physicians were asked to stop
enrollment into that cohort and to continue
enrolling patients only into the other treatment
cohort, as and when they initiate patients on
that treatment according to their usual practice.
Statistical Analysis
All patients eligible at baseline were included in
the analyses. Baseline patient data were
reported using descriptive statistics and 95%
CI where appropriate. For continuous variables
mean, SD, median, minimum, maximum, and
quartiles were calculated. Absolute numbers
and percentages (including missing values)
were given for categorical variables. Per-
country analyses were also performed.
Univariate analyses were performed to
compare all baseline patient characteristics
between the two cohorts (overall population
and per country). Continuous variables were
analyzed using t tests, analyses of variance
(ANOVA), or where necessary the corresponding
nonparametric alternatives (e.g., Wilcoxon
signed rank test). Categorical variables were
analyzed using v2 tests, Fisher’s exact tests, and
trend tests. Logistic regression models were then
applied to identify factors significantly
associated with injectable treatment regimen
(differentiation between exenatide b.i.d. and
insulin), using forward selection processes and
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including only those variables that were
statistically significant (P\0.1) at the
univariate level. For all these analyses missing
data were not imputed.
Logistic regression was also used to derive
propensity scores from baseline data (0.10
threshold for between-cohort differences).
The propensity score estimates the probability
that a patient will be assigned to a treatment
group based on baseline characteristics (score
range 0–1). Propensity score analysis was used
to assess comparability of the treatment
cohorts [11]. For this analysis all eligible
baseline data were included. Missing data
were imputed with the overall mean or
median for continuous variables, and most
frequent category for categorical variables, in
order to give a conservative estimate. Patients
were matched 1:1 by country based on the
propensity score and optimal matching to
identify matched subsets from the two
cohorts. All P values are reported without
multiplicity adjustments.
RESULTS
Between January 2008 and October 2009, 2,513
patients were recruited; 2,492 were eligible for
inclusion in CHOICE. Overall, 1,177 (47.2%)
patients initiated exenatide b.i.d. and 1,315
(52.8%) initiated insulin. Almost half (46%) of
patients initiating insulin received basal-only
insulin, 23% received mixtures, 13% basal-bolus
regimen, 11% short-acting only, and 7% other
or missing, although there was significant
between-country variability. Numbers of
participants in each country were: Belgium,
299 (43.1% exenatide b.i.d.); Denmark, 60
(73.3% exenatide b.i.d.); France, 290 (67.6%
exenatide b.i.d.); Germany, 848 (46.5%
exenatide b.i.d.); Greece, 807 (39.4% exenatide
b.i.d.), and Sweden, 188 (51.1% exenatide
b.i.d.). Of the 325 investigators, 220 (67.7%)
were secondary-care physicians and 23 (7.1%)
were primary-care physicians [‘‘other’’ or
missing data: 82 (25.2%)].
Demographic and Clinical Characteristics
Overall, patients had a mean age of
61 ± 10 years, BMI of 32.3 ± 6.6 kg/m2 and
HbA1c of 8.9 ± 1.7%. Mean duration of
diagnosed diabetes was 9 ± 7 years. Univariate
analyses revealed statistically significant
differences between patients whom clinicians
initiated on exenatide b.i.d. and starter insulin
regimens (collectively referred to as ‘‘insulin’’;
Table 1). Patients initiating exenatide b.i.d.
were on average significantly younger than
those initiating insulin (mean age 58 ± 10 vs.
64 ± 11 years; P\0.0001). This trend was
consistent across all countries except
Denmark, wherein the cohorts did not differ
significantly in age (total n = 60). Patients
initiating exenatide b.i.d. had significantly
higher mean body weight (101.1 ± 21.6 vs.
84.3 ± 17.6 kg; P\0.0001) and mean BMI
(35.3 ± 6.5 vs. 29.7 ± 5.4 kg/m2; P\0.0001)
than those initiating insulin (Table 1), a
finding that was also consistent across all
countries (Fig. 1a). Exenatide b.i.d. patients
also had a higher mean waist circumference in
all countries (nonsignificant difference in
Denmark). Exenatide b.i.d. patients had higher
mean diastolic blood pressure and lower mean
total cholesterol, low-density lipoprotein
cholesterol, and creatinine values. The two
cohorts also differed significantly in
educational status when all subcategories of
educational level were taken into account
(Table 1), although data were available for
only 1,937 patients (77.7% of total) and hence
this was not included in the multivariate
analysis.
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Male, n (%) 635 (54.0) 762 (57.9) 0.0427 1,397 (56.1)
Caucasian, n (%) 970 (82.4) 1,206 (91.7) NS 2,176 (87.3)
Age, years 58 ± 10 64 ± 11 \0.0001 61 ± 11
Weight, kg 101.1 ± 21.6 84.3 ± 17.6 \0.0001 92.2 ± 21.3
BMI, kg/m2 35.3 ± 6.5 29.7 ± 5.4 \0.0001 32.3 ± 6.6
Waist circumference, cm 114.6 ± 14.8 103.3 ± 14.1 \0.0001 108.7 ± 15.5
Blood pressure, mmHg
Systolic 137.8 ± 16.5 137.4 ± 17.4 NS 137.6 ± 17.0
Diastolic 81.6 ± 9.6 80.1 ± 9.9 \0.0001 80.8 ± 9.8
Plasma lipids, mmol/Lb
Total cholesterol 4.93 ± 1.06 5.12 ± 1.23 0.0007 5.03 ± 1.15
LDL cholesterol 2.82 ± 1.09 3.00 ± 1.01 \0.0001 2.91 ± 1.05
HDL cholesterol 1.18 ± 0.34 1.19 ± 0.34 NS 1.19 ± 0.34
Triglycerides 2.37 ± 1.54 2.36 ± 1.99 0.0212 2.36 ± 1.79
Creatinine, mmol/Lb 82.6 ± 40.1 91.1 ± 59.1 \0.0001 87.1 ± 51.3
Smoking status, n (%)
Ever smoked 498 (42.3) 512 (38.9) 0.0307 1,010 (40.5)
Current smoker 178 (15.1) 229 (17.4) NS 407 (16.3)
Employment, n (%) \0.0001c
Working full/part time 483 (41.0) 356 (27.1) 839 (33.7)
Retired 402 (34.2) 681 (51.8) 1,083 (43.5)
Unemployed and other 292 (24.8) 278 (21.1) 570 (22.9)
Education, n (%) \0.0001c
No formal 69 (5.9) 71 (5.4) 140 (5.6)
Minimum mandatory 437 (37.1) 572 (43.5) 1,009 (40.5)
Further education 310 (26.3) 245 (18.6) 555 (22.3)
University 127 (10.8) 106 (8.1) 233 (9.3)
Unknown 229 (19.5) 315 (24.0) 544 (21.8)
Comorbid illness, n (%) 0.0014d
Hypertension 818 (69.5) 859 (65.3) 1,677 (67.3)
Hyperlipidemia 642 (54.5) 641 (48.7) 1,283 (51.5)









Concomitant therapy, n (%)
Any 1,016 (86.3) 1,114 (84.7) NS 2,130 (85.5)
Lipid-lowering 664 (56.4) 712 (54.1) NS 1,376 (55.2)
Cardiovascular 895 (76.0) 972 (73.9) NS 1,867 (74.9)
Antiplatelet 485 (41.2) 599 (45.6) NS 1,084 (43.5)
Weight-lowering 54 (4.6) 20 (1.5) \0.0001 74 (3.0)
Time since diabetes diagnosis, years 8 ± 6 10 ± 7 \0.0001 9 ± 7
HbA1c, most recent in previous
3 months, %
8.4 ± 1.4 9.2 ± 1.9 \0.0001 8.9 ± 1.7
HbA1c\7%, n (%) 126 (10.7) 74 (5.6) – 200 (8.0)
Random blood glucose, mmol/L 10.4 ± 3.1 12.1 ± 4.4 \0.0001 11.4 ± 4.0
Use of SMBG, n (%) 928 (78.8) 1,050 (79.8) NS 1,978 (79.4)
No. of test strips used (per week)e 9.3 ± 7.9 9.9 ± 8.6 NS 9.6 ± 8.3
No. of OADs used (previous 12 months), n (%)
0 197 (16.7) 173 (13.2) – 370 (14.8)
1 379 (32.2) 445 (33.8) – 824 (33.1)
2 467 (39.7) 521 (39.6) – 988 (39.6)
C3 134 (11.4) 176 (13.4) – 310 (12.4)
Antidiabetic medication class used
(previous 12 months), n (%)
Alpha-glucosidase inhibitor 15 (1.3) 21 (1.6) – 36 (1.4)
Biguanide 816 (69.3) 881 (67.0) – 1,697 (68.1)
Biguanide ? sulfonylurea 33 (2.8) 39 (3.0) – 72 (2.9)
DPP-4 inhibitor 81 (6.9) 97 (7.4) – 178 (7.1)
GLP-1 receptor agonist 2 (0.2) 0 (0.0) – 2 (0.1)
Secretion enhancer 75 (6.4) 99 (7.5) – 174 (7.0)
Sulfonylurea 494 (42.0) 682 (51.9) – 1,176 (47.2)
Thiazolidinedione 136 (11.6) 150 (11.4) – 286 (11.5)
Thiazolidinedione ? biguanide 66 (5.6) 39 (3.0) – 105 (4.2)
Thiazolidinedione ? sulfonylurea 2 (0.2) 1 (0.1) – 3 (0.1)
Other 3 (0.3) 4 (0.3) – 7 (0.3)
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Diabetes and Glucose Control
Overall, patients initiating exenatide b.i.d.
reported a significantly shorter mean duration
of diagnosed diabetes than those initiating
insulin (8 ± 6 vs. 10 ± 7 years, respectively;
P\0.0001). This was consistent across all
countries except Belgium (wherein the
durations were similar) and was statistically
significant in France (10 ± 6 vs. 13 ± 9 years;
P\0.01) and Greece (9 ± 6 vs. 12 ± 8 years;
P\0.0001; data not shown). Injectable
therapy was initiated following an increase in
HbA1c during the previous 9–12 months, a
trend consistent across countries. This increase
in HbA1c prior to initiation of injectable therapy
was more pronounced in patients initiating
insulin rather than exenatide b.i.d. At the
point of initiation, patients who initiated
exenatide b.i.d. had a significantly lower mean
HbA1c than those who initiated insulin
(8.4% ± 1.4 vs. 9.2% ± 1.9; P\0.0001). This
was consistent across countries (Fig. 1b).
Overall, 8.0% of patients (200/2,492) initiated
injectable therapy despite having an HbA1c








Patients ever given diet and exercise advice,
n (%)
910 (77.3) 905 (68.8) \0.0001 1,815 (72.8)
Patient with C1 hypoglycemic event
(past 3 months), n (%)
61 (5.2) 58 (4.4) NS 119 (4.8)
No. of hypoglycemic events among
patients with C1 episode
8.2 ± 24.4 5.5 ± 9.5 – 6.8 ± 18.4
Diabetes complications, n (%)
C1 macrovascular complication 212 (18.0) 339 (25.8) \0.0001 551 (22.1)
C1 microvascular complication 173 (14.7) 281 (21.4) \0.0001 454 (18.2)
Consultations to HCPs within the last 6 months
Clinic visits to HCPs, n (%) 1,098 (93.3) 1,233 (93.8) – 2,331 (93.5)
Phone calls to HCPs, n (%) 251 (21.3) 292 (22.2) – 543 (21.8)
No. of clinic visits to HCPs 7.2 ± 7.0 7.7 ± 8.6 – 7.5 ± 7.9
No. of phone calls to HCPs 0.6 ± 1.4 0.72 ± 1.9 – 0.7 ± 1.7
Continuous data are means (SD). –, No statistical analysis performed
b.i.d. twice daily, BMI body mass index, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HbA1c glycated
hemoglobin, HCP healthcare professionals, HDL high-density lipoprotein, LDL low-density lipoprotein, NS non-
signiﬁcant (using threshold for statistical signiﬁcance of P\0.05), OAD oral antidiabetic medication, SMBG self-
monitoring of blood glucose
a Wilcoxon test used for continuous data. v2 or Fisher’s exact tests used for categorical data
b Reported within the last 6 months prior to T1 (initiation)
c Comparisons under ‘‘Employment’’ and ‘‘Education’’ take into account all subcategories under these headings
d Cochrane–Armitage trend test for number of signiﬁcant diagnoses (0, 1, 2, or more)
e Data used are those in only patients who used blood glucose monitoring
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This percentage varied between 0% (Belgium)
and 13.6% (Denmark) for exenatide b.i.d.
(overall 10.7%) and between 0% (Denmark)
and 6.4% (France) for insulin (overall 5.6%; data
not shown). Patients who initiated exenatide
b.i.d. also had significantly lower random blood
glucose values than those who initiated insulin
(Table 1). There were no discernible differences
in patterns of OAD use at the initiation of
injectable therapy between the cohorts
(Table 1), with the possible exception that
sulfonylurea use within the 12 months prior to
inclusion in the study may have been higher in
patients who initiated insulin than in those
who initiated exenatide b.i.d. (although no
statistical analysis was performed to confirm
this). Overall, 5.2% of patients initiating
exenatide b.i.d. and 4.4% of patients initiating
insulin reported experiencing at least one
hypoglycemic episode in the 3 months prior to
baseline. Few patients reported severe or
nighttime episodes (*5%) and there were no
clear differences between cohorts.
Significantly fewer patients initiating
exenatide b.i.d. had reported one or more
macrovascular complication (18.0% vs. 25.8%;
P\0.0001) or microvascular complication
(14.7% vs. 21.4%; P\0.0001), compared with
patients initiating insulin. Differences in the
prevalence of macrovascular complications at
the time of initiation of injectable therapy were
particularly notable in Germany (15.5% vs.
24.2% in the exenatide b.i.d. and insulin
cohorts, respectively; P\0.01), Greece (21.4%
vs. 28.2%; P\0.05), and Sweden (14.6% vs.
29.3%; P\0.05; data not shown). Differences in
the frequency of microvascular complications
were especially notable in France (11.7% vs.




Patients initiating exenatide b.i.d. had a
statistically higher incidence of comorbidities
than patients initiating insulin (P = 0.0014),
i.e., a diagnosis of hypertension (69.5% vs.
65.3%, respectively) and hyperlipidemia
(54.5% vs. 48.7%, respectively). Overall, 85.5%
of patients were using at least one concomitant
Fig. 1 BMI (a) and HbA1c values (b) (most recent during
past 3 months) among patients with type 2 diabetes at the
initiation of exenatide b.i.d. (EX) or insulin (INS) in six
countries. Box plots show mean (triangle), median (line),
25% and 75% quartiles (box) and minimum/maximum
values (whiskers). a *P\0.001, **P\0.0001 for intercohort
comparison (Wilcoxon text), b *P = 0.01, **P = 0.001,
***P\0.0001 for intercohort comparison (Wilcoxon text).
b.i.d. twice daily, BMI body mass index, HbA1c glycated
hemoglobin, NS not signiﬁcant
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(nondiabetes) medication (mainly cardiovascular,
lipid-lowering, and antiplatelet agents) at
initiation of injectable therapy and this was
consistent across countries. There were no
significant differences between cohorts in
the use of cardiovascular, lipid-lowering, or
antiplatelet agents (Table 1). Exenatide b.i.d.
patients were statistically significantly more likely
to have used weight-lowering medications than
insulin patients (4.6% vs. 1.5%, respectively;
P\0.0001).
Resource Use
Overall, 79.4% of patients self-monitored blood
glucose, using a mean of 9.6 ± 8.3 test strips/
week. There were no statistically significant
differences between the cohorts in the number
of contacts with healthcare professionals in the
6 months prior to baseline (Table 1).
Factors Associated with Injectable
Treatment Regimen and Propensity Score
A multiple logistic regression analysis (forward
selection) identified BMI, age, and HbA1c as the
variables most strongly associated with a
propensity for treatment assignment, with
higher BMI, lower age, and lower HbA1c
indicating an increased probability of receiving
exenatide b.i.d. (Table 2); [odds ratio (OR)
exenatide b.i.d. vs. insulin: BMI (5 kg/m2
higher) 2.10, 95% CI 1.84–2.40; HbA1c (1%
higher): OR 0.77, 95% CI 0.69–0.86; age (5 years
older) OR 0.82, 95% CI 0.76–0.88; all
P\0.0001). Other statistically significant
factors associated with the treatment regimen
were the ‘‘Disinhibited Eating Subscale’’ of the
DHP-18 (which comprises five items that
measure lack of eating control, response to
food cues, and emotion [8]), random blood
glucose, use of self-monitoring of blood glucose,
receipt of diet/exercise advice, and low-density
lipoprotein cholesterol (Table 2).
A propensity score analysis based on baseline
demographic and clinical variables underlined
the differences between the treatment cohorts.
The mean propensity score value for the
probability of receiving exenatide b.i.d. was
0.63 ± 0.23, and of receiving insulin was
0.33 ± 0.23 (Table 3). Evaluation of propensity
score quintiles indicated that 51% of patients
could be matched (1,278 patients, 639 per
cohort), largely representing the upper tail of
the exenatide b.i.d. distribution and the lower
tail of the insulin distribution.
DISCUSSION
Well-designed, observational (‘‘real-world’’)
studies are essential to enhancing the evidence
upon which the management of T2DM is based
[5]. The CHOICE study, a large prospective
observational study conducted in six European
countries, has provided the first available data on
the way exenatide b.i.d. is used in clinical
practice across Europe. The present report
focuses on the baseline characteristics of
patients and it identifies differences between
patients who initiate exenatide b.i.d. and those
who initiate starter insulin at the discretion of
the treating physician. As well as being of
intrinsic interest, these data will also have
implications for the comparability of clinical
outcomes between the CHOICE cohorts in future
publications, and perhaps for the comparability
between exenatide b.i.d. and insulin data from
clinical practice more generally.
Overall, patients initiating exenatide b.i.d.
were characterized by: younger age; higher body
weight, BMI, and waist circumference; higher
diastolic blood pressure, lower total and LDL
cholesterol levels; shorter time since diabetes
diagnosis; and better glycemic control. A lower
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Table 2 Baseline variables that were statistically signiﬁcantly associated with initiating exenatide b.i.d. compared with
insulin (logistic regression using forward selection of variables signiﬁcant in univariate analysis at threshold of P\0.10)
Variable OR 95% CI P value
Body mass index
1 kg/m2 higher 1.16 1.13–1.19 \0.0001
5 kg/m2 higher 2.10 1.84–2.40 \0.0001
Most recent HbA1c: 1% higher 0.77 0.69–0.86 \0.0001
Age
1 year older 0.96 0.95–0.97 \0.0001
5 years older 0.82 0.76–0.88 \0.0001
10 years older 0.67 0.58–0.77 \0.0001
DHP-18 subscale: disinhibited eating (yes vs. no) 1.05 1.01–1.10 0.0083
Random blood glucose: 1 mmol/L higher 0.94 0.90–0.99 0.0141
Blood glucose self-monitoring
1 test/week more 0.98 0.96–0.99 0.0107
5 tests/week more 0.88 0.81–0.96 0.0042
10 tests/week more 0.78 0.66–0.92 0.0042
Receipt of diet/exercise advice (yes vs. no) 1.67 1.13–2.46 0.0193
LDL cholesterol: 1 mmol/L higher 0.83 0.72–0.96 0.0138
CI conﬁdence interval, b.i.d. twice daily, DHP-18 Diabetes Health Proﬁle-18, HbA1c glycated hemoglobin, LDL low-density
lipoprotein, OR odds ratio exenatide b.i.d. versus insulin (OR values [1 indicate variables that were associated with
increased probability of receiving exenatide b.i.d., OR values\1 indicate variables associated with decreased probability of
receiving exenatide b.i.d.)
Table 3 Overall propensity scores and distribution by quintile for each cohort
Exenatide b.i.d. (n5 1,177) Insulin (n5 1,315)
Mean score: 0.63 – 0.23 0.33 – 0.23
Quintile n (%) Mean score n (%) Mean score
1 42 (3.6) 0.13 ± 0.04 456 (34.7) 0.11 ± 0.05
2 145 (12.3) 0.29 ± 0.05 353 (26.8) 0.27 ± 0.05
3 241 (20.5) 0.46 ± 0.05 258 (19.6) 0.45 ± 0.05
4 327 (27.8) 0.65 ± 0.06 171 (13.0) 0.64 ± 0.05
5 422 (35.9) 0.87 ± 0.07 77 (5.9) 0.84 ± 0.06
Quintiles calculated over both cohorts combined
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proportion of patients initiating exenatide b.i.d.
had microvascular and macrovascular
complications (compared with patients
initiating insulin), a finding that might reflect
their younger mean age, glycemic control
(HbA1c), and duration of diabetes. The
differences between the two cohorts in key
variables such as age, obesity measures, and
HbA1c were consistent across the participating
countries, although the statistical significance
of some inter-cohort differences was limited by
the sample size in individual countries. Overall
BMI, HbA1c, and age were factors significantly
associated with differentiation between
exenatide b.i.d. and insulin (P\0.0001).
The risk of treatment-induced hypoglycemia is
an important consideration during treatment
selection [1–3], especially in patients with an
HbA1c close to or within target levels; the recently
published American Diabetes Association (ADA)/
European Association for the Study of Diabetes
(EASD) consensus statement for T2DM
management specifies exenatide b.i.d. as an
option when hypoglycemia is a particularly
important consideration [7]. Consistent with
this proposed treatment algorithm, the
frequency of recent hypoglycemia in CHOICE
was numerically higher in patients who initiated
exenatide b.i.d. than in the insulin cohort, but
the number of affected patients was small and the
difference was not statistically significant.
The finding that exenatide b.i.d. was favored
in patients with higher body weight is not
surprising. Patients treated with exenatide
b.i.d. show significant weight loss compared
with those treated with insulin [1–3]. The ADA/
EASD consensus statement and the American
Association of Clinical Endocrinologists
treatment algorithm identify the use of
exenatide b.i.d. as an option when weight loss
is a major consideration [7, 12].
The mean HbA1c level in both cohorts in
CHOICE exceeded the recommended target
level of \7% [7] prior to the initiation of
injectable therapy. Mean HbA1c levels rose
gradually during the 18–24 months prior to
baseline. A steeper rise occurred in the
6 months prior to baseline and this appeared
more marked in the insulin cohort (reaching
9.2%) than in the exenatide b.i.d. cohort
(reaching 8.4%). Although this finding may
reflect different disease progression in the two
cohorts prior to the initiation of either
exenatide b.i.d. or insulin, missing pre-
baseline HbA1c records in some patients make
interpretation of this phenomenon difficult.
These findings are consistent with previous
observational evidence that insulin initiation
is very often delayed for years despite poor
glycemic control on oral glucose-lowering
medications [9, 13–15].
The finding that patients initiating exenatide
b.i.d. in CHOICE had lower HbA1c levels than
those initiating insulin is consistent with US
observational data [16] and with the ADA/EASD
consensus statement that identifies exenatide
b.i.d. as an option for patients with glycemic
control closer to target levels [7]. However,
clinical data support use of exenatide b.i.d. at
various ranges of HbA1c including high values
([9%) and not only where HbA1c is close to
target levels [17–19]. The consistently higher
baseline blood glucose values observed among
insulin patients, coupled with a longer time
since diagnosis, may indicate that exenatide
b.i.d. is used earlier in the disease to intensify
therapy and thereby delay the need for insulin
initiation. A minority of patients initiated
insulin (10.7%) or exenatide b.i.d. (5.6%)
despite having a baseline HbA1c of \7%.
The observation (on univariate analysis) of a
higher proportion of diagnosed dyslipidemia or
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hypertension inpatients initiating exenatide b.i.d.
is of unclear significance but may be related to
body weight. Similar findings were observed in the
aforementioned retrospective database analysis in
the United States [16]. In common with CHOICE,
this previous analysis also found that patients
initiating exenatide b.i.d. had significantly lower
rates of macrovascular and microvascular
complications than those initiating insulin [16].
Overall, the mean blood pressure values among
CHOICE patients at baseline would classify the
population at low risk according to the target
of 130/80 mmHg recommended by the
International Diabetes Federation [20], and a
Task Force of the European Society of Cardiology
and the EASD [21]. Even if blood pressure values
were elevated, hypertension is unlikely to be a
driverof treatmentchoice independentlyofHbA1c
and weight. Patients who initiated insulin had
significantly higher creatinine levels than those
who initiated exenatide b.i.d. This could reflect
the higher mean age in the insulin cohort. It is also
possible that renal complications, as well as other
complications, might have contributed to the
initiation of insulin. The lack of data on
glomerular filtration rate hampers interpretation
of the creatinine data.
Univariate analyses showed that patients
receiving exenatide b.i.d. were more likely than
insulin recipients to be employed. Primary
occupational status was correlated with age,
and only age showed a significant association
with treatment selection in the multivariate
analysis. The higher educational status in the
exenatide b.i.d. cohort compared with the
insulin cohort on univariate analysis may
reflect the possibility that more educated
patients are more likely to ask for newer
treatments, but this is speculation. Educational
status was not included in the multivariate
analysis owing to a relatively high proportion
of missing data.
The CHOICE study has several limitations.
While the data allow a multivariate analysis to
help improve the understanding of the
measured variables most strongly associated
with the choice of injectable therapy, other
variables that were not captured, such as clinical
guidelines and patient preference, may be at
least as clinically relevant. As significant
differences between the cohorts are present,
outcome results observed in these groups are
not directly comparable. The matched
population refers to those patients in whom
outcomes can be statistically compared.
However, this largely represents the upper
tail of the exenatide b.i.d. propensity score
distribution and the lower tail of the insulin
distribution. Therefore, caution is advised
when interpreting comparative outcomes.
Although CHOICE was designed to recruit a
representative sample of patients, the degree
to which the data can be generalized is
unclear for several reasons. Firstly, patients
were mostly recruited in secondary-care
centers and hence the data may not be
generalizable to the primary-care setting.
Secondly, the similarity in the size of the
exenatide b.i.d. and insulin cohorts does not
reflect the ratio in routine clinical practice,
wherein many more patients initiate insulin
than exenatide b.i.d. The CHOICE population
appears similar to that of the observational
‘‘Insulin titration; gaining an understanding
of type 2 diabetes in Europe’’ (INSTIGATE)
study [9], which looked at T2DM patients
initiating insulin therapy, in terms of such
variables as mean age, BMI, and duration of
diabetes among participants, although
INSTIGATE patients had a higher mean
HbA1c at the initiation of insulin (9.6% vs.
9.2% in CHOICE). The small sample size in
some countries reduces the statistical power of
the inter-cohort analysis. The variation in
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sample sizes between the six countries
also limits the robustness of inter-country
comparisons, although the inter-cohort
comparisons nevertheless showed a considerable
degree of international consistency. There was
also variation between countries in the ratios of
exenatide b.i.d. and insulin patients.
In conclusion, this analysis has improved
understanding of which patients are initiated
on exenatide b.i.d. or insulin in routine clinical
practice. The cohort of patients who initiated
exenatide b.i.d. in CHOICE was younger, more
obese, and had a lower HbA1c than those who
initiated insulin. These differences appear to
reflect the recommendations for the use of these
two therapies, with exenatide b.i.d. identified as
an option when weight gain is a particular
concern and when HbA1c is modestly raised
[7, 12]. The data suggest that the patient profile
may contribute to the prescribing of injectable
glucose-lowering therapy regimen for patients
with T2DM.
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